Trial · NCT02780726
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hemoglobin (Hb) Response Rate from Week 18 to Week 24 | Up to Week 24 | Hb response defined as average Hb within the target range in this outcome |
| Secondary | Hb Response rate | Up to Week 24 | Hb response is defined as reaching target values for Hb and change of Hb from baseline in this outcome. |
| Secondary | Average Hb levels from week 18 to week 24 | Up to week 24 | |
| Secondary | Change from baseline in the average Hb levels of week 18 to week 24 | Baseline and up to Week 24 | |
| Secondary | Rate of rise in Hb levels (g/dL/week) | Up to Week 4 | |
| Secondary | Proportion of time points with target Hb levels | Up to Week 24 | |
| Secondary | Proportion of participants who achieve the target Hb level at each week | Up to Week 24 | |
| Secondary | Proportion of participants who achieve the lower limit of the target Hb level | Up to Week 24 | |
| Secondary | Time to achieve the lower limit of the target Hb level | Up to Week 24 | |
| Secondary | Change from baseline in Hb level at each week | Baseline and Up to Week 24 | |
| Secondary | Efficacy assessed by hematocrit | Up to Week 24 | Hematocrit will be summarized by ASP1517 low dose Erythropoieses Stimulating Agent (ESA) untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group. |
| Secondary | Efficacy assessed by reticulocytes/ erythrocytes | Up to Week 24 | Reticulocytes/Erythrocytes will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group. |
| Secondary | Efficacy assessed by Iron (Fe) | Up to Week 24 | Fe will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group. |
| Secondary | Efficacy assessed by ferritin | Up to Week 24 | Ferritin will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group. |
| Secondary | Efficacy assessed by transferrin | Up to Week 24 | Transferrin will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group. |
| Secondary | Efficacy assessed by total iron binding capacity | Up to Week 24 | Total iron binding capacity will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group. |
| Secondary | Efficacy assessed by soluble transferrin receptor | Up to Week 24 | Soluble transferrin receptor will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group. |
| Secondary | Efficacy assessed by transferrin saturation | Up to Week 24 | Transferrin saturation will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group. |
| Secondary | Efficacy assessed by reticulocyte hemoglobin content | Up to Week 24 | Reticulocyte hemoglobin content will be summarized by ASP1517 low dose ESA untreated group, ASP1517 high dose ESA untreated group and ASP1517 ESAs treated Group. |
| Secondary | Quality of life assessed by SF-36 | Up to Week 24 | SF-36: Medical Outcomes Study 36-Item Short-Form Health Survey |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02780726/registered